Deanna H. Pafundi

TL;DR: This review provides an overview of the clinical literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.

TL;DR: F-DOPA PET SUV(max) may more accurately identify regions of higher-grade/higher-density disease in patients with astrocytomas and will have utility in guiding stereotactic biopsy selection.

TL;DR: In this article, the relationship between LAT1 expression and 18F-DOPA uptake in human glioblastoma (GBM) cells was investigated using Western blotting and reverse transcription polymerase chain reaction (qRT-PCR).

TL;DR: Different implementations of perfusion MR imaging software modeling can impact the accuracy of leakage correction, relative CBV calculation, and correlations with histologic benchmarks.

TL;DR: Assessment of region-specific penetrance and molecular-targeting capacity for a PI3K/mTOR kinase inhibitor that has high substrate affinity for efflux transporters and an analog that was purposely designed to have reduced efflux show that BBB efflux by P-gp and BCRP is therefore an important determinant in both brain penetration and molecular targeting efficacy in the treatment of invasive glioma cells.